» Articles » PMID: 39267037

Spatial Transcriptomics Reveals Tumor-derived SPP1 Induces Fibroblast Chemotaxis and Activation in the Hepatocellular Carcinoma Microenvironment

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2024 Sep 12
PMID 39267037
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The tumor microenvironment (TME) exerts profound effects on tumor progression and therapeutic efficacy. In hepatocellular carcinoma (HCC), the TME is enriched with cancer-associated fibroblasts (CAFs), which secrete a plethora of cytokines, chemokines, and growth factors that facilitate tumor cell proliferation and invasion. However, the intricate architecture of the TME in HCC, as well as the mechanisms driving interactions between tumor cells and CAFs, remains largely enigmatic.

Methods: We analyzed 10 spatial transcriptomics and 12 single-cell transcriptomics samples sourced from public databases, complemented by 20 tumor tissue samples from liver cancer patients obtained in a clinical setting.

Results: Our findings reveal that tumor cells exhibiting high levels of SPP1 are preferentially localized adjacent to hepatic stellate cells (HSCs). The SPP1 secreted by these tumor cells interacts with the CD44 receptor on HSCs, thereby activating the PI3K/AKT signaling pathway, which promotes the differentiation of HSCs into CAFs. Notably, blockade of the CD44 receptor effectively abrogates this interaction. Furthermore, in vivo studies demonstrate that silencing SPP1 expression in tumor cells significantly impairs HSC differentiation into CAFs, leading to a reduction in tumor volume and collagen deposition within the tumor stroma.

Conclusions: This study delineates the SPP1-CD44 signaling axis as a pivotal mechanism underpinning the interaction between tumor cells and CAFs. Targeting this pathway holds potential to mitigate liver fibrosis and offers novel therapeutic perspectives for liver cancer management.

Citing Articles

Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions.

Xin Y, Ma Q, Deng Q, Wang T, Wang D, Wang G Front Immunol. 2025; 16:1521388.

PMID: 40079015 PMC: 11897037. DOI: 10.3389/fimmu.2025.1521388.


Identification of the entosis-related prognostic signature and tumour microenvironment in hepatocellular carcinoma on the basis of bioinformatics analysis and experimental validation.

Wu C, Fang S, Wu L, Mi Z, Yin Y, Liao Y Clin Exp Med. 2025; 25(1):55.

PMID: 39937284 PMC: 11821697. DOI: 10.1007/s10238-025-01580-8.

References
1.
Sharma A, Seow J, Dutertre C, Pai R, Bleriot C, Mishra A . Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell. 2020; 183(2):377-394.e21. DOI: 10.1016/j.cell.2020.08.040. View

2.
Donne R, Lujambio A . The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2022; 77(5):1773-1796. PMC: 9941399. DOI: 10.1002/hep.32740. View

3.
Ali I, Wani W, Haque A, Saleem K . Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem. 2013; 5(8):961-78. DOI: 10.4155/fmc.13.62. View

4.
Bejarano L, Jordao M, Joyce J . Therapeutic Targeting of the Tumor Microenvironment. Cancer Discov. 2021; 11(4):933-959. DOI: 10.1158/2159-8290.CD-20-1808. View

5.
Hao Y, Hao S, Andersen-Nissen E, Mauck 3rd W, Zheng S, Butler A . Integrated analysis of multimodal single-cell data. Cell. 2021; 184(13):3573-3587.e29. PMC: 8238499. DOI: 10.1016/j.cell.2021.04.048. View